Table 3.
AEs and severity.
| RT + TTFields (N = 10) | |||
|---|---|---|---|
| AEs | Total | Grade 1–2 | Grade 3–4 |
| Patients with ≥ 1 AE, n (%) | 10 (100) | 6 (60) | 4 (40) |
| Local complications, n (%) | 8 (80) | 8 (80) | 0 |
| Scalp skin complications | 8 (80) | 8 (80) | 0 |
| Application site blisters | 1 (10) | 1 (10) | 0 |
| Application site erosions | 3 (30) | 3 (30) | 0 |
| Application site erythema | 4 (40) | 4 (40) | 0 |
| Contact dermatitis | 4 (40) | 4 (40) | 0 |
| Dermatitis | 1 (10) | 1 (10) | 0 |
| Eczema | 1 (10) | 1 (10) | 0 |
| Pruritus | 1 (10) | 1 (10) | 0 |
| Seborrheic keratosis | 1 (10) | 1 (10) | 0 |
| Systemic complications, n (%) | 8 (80) | 4 (40) | 4 (40) |
| Gastrointestinal disorders | 3 (30) | 3 (30) | 0 |
| Abdominal pain | 1 (10) | 1 (10) | 0 |
| Constipation | 2 (20) | 2 (20) | 0 |
| Hematochezia | 1 (10) | 1 (10) | 0 |
| Nausea | 1 (10) | 1 (10) | 0 |
| Vomiting | 1 (10) | 1 (10) | 0 |
| General disorders | 6 (60) | 5 (50) | 1 (10) |
| Asthenia | 1 (10) | 1 (10) | 0 |
| Chest pain | 1 (10) | 1 (10) | 0 |
| Fatigue | 4 (40) | 4 (40) | 0 |
| Gait disturbance | 1 (10) | 1 (10) | 0 |
| General physical health deterioration | 1 (10) | 0 | 1 (10) |
| Performance status decreased | 1 (10) | 1 (10) | 0 |
| Weight decreased | 1 (10) | 1 (10) | 0 |
| Injury, poisoning, and procedural complications | 1 (10) | 1 (10) | 0 |
| Spinal compression fracture | 1 (10) | 1 (10) | 0 |
| Laboratory abnormalities | 3 (30) | 2 (20) | 1 (10) |
| Anemia | 1 (10) | 1 (10) | 0 |
| Blood creatine phosphokinase increased | 1 (10) | 1 (10) | 0 |
| Blood lactate dehydrogenase increased | 2 (20) | 2 (20) | 0 |
| Iron deficiency | 1 (10) | 1 (10) | 0 |
| Lymphopenia | 1 (10) | 0 | 1 (10) |
| Platelet count decreased | 2 (20) | 2 (20) | 0 |
| Vitamin D deficiency | 1 (10) | 1 (10) | 0 |
| Nervous system disorders | 5 (50) | 3 (30) | 2 (20) |
| Cognitive disorder | 1 (10) | 1 (10) | 0 |
| Hemorrhage intracranial | 1 (10) | 0 | 1 (10) |
| Hemiparesis | 1 (10) | 1 (10) | 0 |
| Neurological decompensation | 4 (40) | 2 (20) | 2 (20) |
| Quadrantanopia | 1 (10) | 1 (10) | 0 |
| Speech disorder | 1 (10) | 1 (10) | 0 |
| Other skin and subcutaneous tissue disorders | 1 (10) | 1 (10) | 0 |
| Decubitus ulcer | 1 (10) | 1 (10) | 0 |
| Psychiatric disorders | 2 (20) | 2 (20) | 0 |
| Abnormal behavior | 1 (10) | 1 (10) | 0 |
| Affective disorder | 1 (10) | 1 (10) | 0 |
| Confusional state | 1 (10) | 1 (10) | 0 |
| Delirium | 1 (10) | 1 (10) | 0 |
| Insomnia | 2 (20) | 2 (20) | 0 |
| Restlessness | 1 (10) | 1 (10) | 0 |
| Renal and urinary disorders | 2 (20) | 2 (20) | 0 |
| Urinary incontinence | 1 (10) | 1 (10) | 0 |
| Urinary tract infection | 1 (10) | 1 (10) | 0 |
AE, adverse event; RT, radiation therapy.